FDA approves NuPathe's Zecuity for migraines

NuPathe Inc. (NASDAQ:PATH) said FDA approved an NDA for Zecuity for the acute treatment of migraine with or without aura in adults. The company, which said it has not yet determined pricing, plans to ...